525 results about "Animal disease" patented technology

Provided are immediate or prolonged administration of certain potassium ATP (KATP) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of KATP channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering KATP channel openers with other drugs to treat diseases of humans and animals.

Disclosed are antisense oligonucleotide, polynucleotide, and peptide nucleic acid compounds that specifically bind to mammalian mRNA encoding a beta1-adrenoceptor polypeptide and that are useful in the control and / or treatment of cardiac dysfunction, hypertension, hypertrophy, myocardial ischemia, and other cardiovascular diseases in an affected mammal, and preferably, in a human subject. The antisense compounds disclosed herein, and pharmaceutical formulations thereof, provide sustained control of beta1-adrenoceptor expression over prolonged periods, and achieve therapeutic effects from as little as a single dose. Administration of these antisense compositions to approved animal models resulted in a decrease in blood pressure, but no significant change in heart rate. Use of such antisense compositions in the reduction of beta1-adrenoceptor polypeptides in a host cell expressing beta1-adrenoceptor-specific mRNA, and in the preparation of medicaments for treating human and animal diseases, and in particular, hypertension and other cardiac dysfunction is also disclosed.

The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

Compositions of matter that comprise one or more conformational epitopes found on amyloid peptide aggregates, antibodies to such epitopes and methods for making and using the compositions, eptitopes and / or antibodies. The invention includes synthetic or isolated compositions that contain or consist of certain conformational epitopes that are found on peptide aggregates (e.g., toxic peptide aggregates) present in human or veterinary patients who suffer from, or who are likely to develop, amyloid diseases (e.g., Alzheimer's Disease). The invention includes methods for the detection, treatment and prevention of diseases in humans or animals, using such compositions. The invention further includes antibodies which bind to the conformational epitopes as well as methods for making such antibodies and methods for the detection, treatment and prevention of diseases and / or identification of potential therapies (e.g., drug screening) using such antibodies.

The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.

The present invention is a medical device for controlling the release of an active agent. The medical device has a supporting structure having a porous body disposed therein. At least one elution rate controlling matrix containing an effective amount of at least one active agent is disposed within the pores of the porous body in a manner that protects the matrix from mechanical damage. The medical device may therefore be used for controlled drug release applications. Additionally, the present invention discloses a method for using the medical device for the treatment and prevention of diseases in mammals. This invention further relates to a method for using the medical device for treating and preventing vascular diseases.

The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.

The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue to the polypeptide. Also provided are methods of making the peptides of the invention and methods, pharmaceutical compositions containing the peptides and methods of treating, ameliorating or preventing diseased in mammals by administering an amount of a peptide of the invention sufficient to achieve the desired response.

Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

Compositions and methods for treating mammalian disease characterized by undesirable angiogenesis by administering compounds of the general formula: wherein the variables are defined in the specification.

The present invention relates to an active peptide feed addictive, as a mixture of one or more plant protein and animal protein, which is the product of the following steps: fermenting and degrading the mixture through bacillus and the like, controlling the degree of hydrolysis at 20-35%, obtaining a fermentation supernatant after a separation post-processing process, concentrating drying the supernatant or directly adsorbing the supernatant onto the carrier, and then low temperature drying it. Said active peptide feed addictive is capable of obviously depressing development of bacillus coli and salmonella, and can prevention and cure diarrhea caused by bacilli or lienteric diarrhea; can exert its functions at a very low concentration, with a very intense effect; can regulate stomach and intestine bacterium group and promote animals digestion functions; can excite animal immune function, reinforce animal disease resistance against a plurality of epidemic diseases and greatly reduce the morbidity and death rate; can promote animal development and improve the growth velocity; can improve the feed use ratio and reduce production costs. Applications of the microorganism fermentation degradation method provided by the present invention have a low fabricating cost, and the obtained peptides have many kinds and high content, without environment pollutions.

The present invention relates to compositions and methods of treating a disease, such as diabetes, by implanting encapsulated biological material with a growth factor and conjugate into a patient in need of treatment. Several methods are presented to accomplish transplanting several different types of biological materials. This invention also provides methods of utilizing these encapsulated biological materials to treat different human and animal diseases or disorders by implanting them into several areas in the body including the subcutaneous site.

The invention relates to enterococcus faecium for feeding as well as a freeze-drying fungicide and applications thereof, and discloses enterococcus faecium LAB12 CGMCC (China General Microbiological Culture Collection Center) No.4847 which is grampositive cocci, has no spores, grows well on an MRS agar plate, forms a round bacterial colony with the diameter of 0.5-1mm within 48 hours and is used for feeding, and the bacterial colony is round, smooth and upheaved, and is a shape of grey white dewdrop; the enterococcus faecium grows in a facultative anaerobic condition; the growth temperature range is 10 DEG C-45 DEG C; the optimum growth temperature is 30 DEG C-40 DEG C; and the growth pH value is 4-10, and the optimum pH value is 6.0. The freeze-drying fungicide formed by the bacterial strain is nontoxic and harmless, is gastric juice resistant, is cholate resistant, has a high inhibitory effect for multiple harmful bacteria, has a long quality guarantee period, can be widely applied to birds and livestock breeding to strengthen the animal disease-resistant capability, and is expected to be the substitution of antibiotics for feeding.

The present invention discloses a composition and method of providing ionic forms or compounds of any combination of three metals to produce a product that can be used as a antimicrobial as defined by the U.S. Environmental Protection Agency (EPA) such as a hard surface disinfectant and as a foliar spray or water treatment for the control of various diseases in garden row, field and tree crops, on hard surface areas such as equipment from infected fields or in hospitals, homes, etc. as well as against a wide range of human, plant and animal diseases. Additionally, the composition of the present invention is able to be used to coat and otherwise treat and disinfect food products such as but not limited to fish and shellfish, meat, milk, poultry, eggs and irrigated crops (both food and nonfood crops) as well as non food products as defined in the EPA exemption from tolerance for copper and copper products. The composition may include inerts such as surfactants, detergents and buffers to adjust the pH. The composition remains soluble in water and is useful efficacious against the spread of bacteria, viruses and fungi and other pathogens within a source of water such as a reservoir or pool. Alternatively, the composition may be in aerosolized, misted, vaporized, fogged, humidified forms to produce micronized particles which are able to remain in suspension in the air for long periods of time in order to act on air-borne fungal spores and / or pathogens.

A method for culturing the Se-enriched edible fungus includes such steps as preparing culture medium from corn cob, straw powder, rice (or wheat) bran, gypsum, magnesium sulfate, zinc sulfate, Se salt and water, loading it in bogs, sealing, sterilizing, inoculating edible fungus spawn, fermenting, culturing mycelia, and spraying Se-enriched nutritive liquid. A method for producing Se-enriched milk by use of the leftover generated by culturing Se-enriched edible fungus features that the leftover is used as the additive of feed for quantitatively feeding the milk cow.

The present invention is directed to palatable ductile chewable veterinary composition for oral administration. The composition is capable of killing endo-parasites and ecto-parasites and / or can be used for treating prophylactic or curative animal diseases, and it is useful for the treatment of any warm-blooded non-human animal, including herd animals, like horses, cattle, sheep or poultry and preferably pets like dogs and cats. It consists basically of (A) an effective amount of one or more ingredients that are active against animal pests, pathogens or animal diseases; (B) meat flavoring; (C) partially gelatinized starch; (D) a softener; and (E) up to 9% water.

The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof.

The present invention relates to novel compounds selected from 2-(3-aminoaryl)amino-4-aryl-thiazoles that selectively modulate, regulate, and / or inhibit signal transduction mediated by certain native and / or mutant tyrosine kinases implicated in a variety of human and animal diseases such as cell proliferative, metabolic, allergic, and degenerative disorders. More particularly, these compounds are potent and selective c-kit inhibitors.

The invention discloses a technique for preparing antimicrobial peptide by using Bacillus subtilis, belonging to the technical field of bioengineering. By using Bacillus subtilis BRT39 capable of generating broad-spectrum high-efficiency antimicrobial peptide as a production strain, liquid seed preparation, fermentation liquid preparation, fermentation liquid pretreatment, antimicrobial peptide extraction and refinement, antimicrobial peptide dry powder preparation and other techniques are carried out to prepare the high-purity antimicrobial peptide finished product, wherein the activity recovery rate is up to higher than 43.5%. The invention has the advantages of simple technique, high yield of antimicrobial peptide, and high purity; the prepared antimicrobial peptide dry powder belongs to a natural antimicrobial agent and has no toxic or side effect, and thus, can be used as a food preservative, feed additive, agricultural biological control agent or animal disease preventing agent; and the antimicrobial peptide has the advantages of no toxicity, no residue, no drug resistance and high safety.

The present invention is directed to novel nucleotide and amino acid sequences of Torque teno virus (“TTV”), including novel genotypes thereof, all of which are useful in the preparation of vaccines for treating and preventing diseases in swine and other animals. Vaccines provided according to the practice of the invention are effective against multiple swine TTV genotypes and isolates. Diagnostic and therapeutic polyclonal and monoclonal antibodies are also a feature of the present invention, as are infectious clones useful in the propagation of the virus and in the preparation of vaccines. Particularly important aspects of the invention include vaccines that provide TTV ORF1 protein, or peptide fragments thereof, as antigen.

Methods and kits for determining appropriate treatment for illnesses in humans or animals are disclosed. The method includes:providing a test kit containing a random arrangement of drug(s) and placebo(s) and / or alternative treatment(s) along with a questionnaire or other instrument designed to elicit data concerning the safety, efficacy and desirability of a treatment;administering the drug(s) and placebo(s) and / or alternative treatments to each member of the pool in a random, double blind fashion and following up on patient outcomes as appropriate post-study;assembling a database from the completed pool questionnaires and revealing the random schedule to uncover drug and placebo treatment periods;providing the same kit to a patient in need of the same treatment and comparing the results obtained from the single patient trial with those obtained from the pool to determine an optimal treatment for the patient with the drug; andadministering a treatment consistent with the optimal treatment.

The present disclosure provides for a scientific formulation useful in the treatment and prevention of human and animal diseases. A biologically effective amount of each of the components of the formulation is administered to patients in pill (or capsule) form via multiple different and identifiable pills. The compounds of the formulation are segregated into different pill types, and contain various amounts of the compounds Curcumin, Genistein, Squalamine, Vitamin E, N-Acetyl-Cysteine, Methylselenocysteine, Zinc Gluconate, B Complex, Lentinen, Coenzyme Q10 Acetyl-L-Carnitine, Lipoic Acid, Resveratrol, and Vitamin C. Furthermore, Arabinoxylan and / or Peperine may be added to the various pill formulations.

The invention discloses a full-automatic animal carcass harmless treatment device. A power supply system, a closed container, a grinding system, a feeding system, a communication and electric control system, a temperature control heating system, a filtration system, a circulation system and a purification system are arranged on a trailer of a vehicle-mounted system of the device, wherein the grinding system is arranged in the closed container; the feeding system feeds materials into the closed container; the temperature control heating system heats the materials in the closed container; the filtration system disinfects steam which is generated in the closed container; the circulation system carries out filtration treatment and waste heat recovery on the materials; and the communication and electric control system is the system control device of the full-automatic animal carcass harmless treatment device. The animal carcass treatment device can completely inactivates common pathogenic microorganisms, and thoroughly realizes harmless treatment; and the device is an important technology and equipment for the emergency disposal of national and local serious animal diseases.

The present invention enables testing the effect of one or more test agent(s) on one or more animal(s) of a group of animals, preferably insects, to identify agents that affect behavioral properties of the animals. The invention is comprised of the steps of providing animals suitable for testing, bringing those animals into contact with the test agent(s), moving the animals from a growth container to isolate them, prepare and separate the animals for singulation, relocated the animals to a behavior arena, subject the animals to behavioral tracking to assess their behavioral state, and removing the animals from the behavioral tracking to facilitate iterative analysis of further groups. The invention enables a method for preparing a therapeutic compound for the treatment of an animal disease.

Provided are immediate or prolonged administration of certain salts of KATP channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KATP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs to treat diseases of humans and animals.

One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.